175 related articles for article (PubMed ID: 2261347)
21. Maintenance treatment with interferon alpha-2b in multiple myeloma: a prospective randomized study from PETHEMA (Program for the Study and Treatment of Hematological Malignancies, Spanish Society of Hematology).
Bladé J; San Miguel JF; Escudero ML; Fontanillas M; Besalduch J; Gardella S; Arias J; García-Conde J; Carnero M; Marti JM; Rozman C; Estapé J; Montserrat E
Leukemia; 1998 Jul; 12(7):1144-8. PubMed ID: 9665202
[TBL] [Abstract][Full Text] [Related]
22. Interferon therapy during the plateau phase of multiple myeloma: an update of the Swedish study.
Westin J; Cortelezzi A; Hjorth M; Rödjer S; Turesson I; Zador G
Eur J Cancer; 1991; 27 Suppl 4():S45-8. PubMed ID: 1799477
[TBL] [Abstract][Full Text] [Related]
23. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial.
Mateos MV; Richardson PG; Schlag R; Khuageva NK; Dimopoulos MA; Shpilberg O; Kropff M; Spicka I; Petrucci MT; Palumbo A; Samoilova OS; Dmoszynska A; Abdulkadyrov KM; Schots R; Jiang B; Esseltine DL; Liu K; Cakana A; van de Velde H; San Miguel JF
J Clin Oncol; 2010 May; 28(13):2259-66. PubMed ID: 20368561
[TBL] [Abstract][Full Text] [Related]
24. Melphalan/prednisone versus melphalan/prednisone plus human alpha interferon therapy in patients with multiple myeloma, stages II and III. Myeloma Group of Central Sweden.
Björkholm M
Eur J Cancer; 1991; 27 Suppl 4():S51-2. PubMed ID: 1799480
[No Abstract] [Full Text] [Related]
25. Interferon alfa-2b versus no maintenance therapy during the plateau phase in multiple myeloma: a randomized study. Cooperative Study Group.
Westin J; Rödjer S; Turesson I; Cortelezzi A; Hjorth M; Zador G
Br J Haematol; 1995 Mar; 89(3):561-8. PubMed ID: 7734355
[TBL] [Abstract][Full Text] [Related]
26. Effect of interferon on the health-related quality of life of multiple myeloma patients: results of a Nordic randomized trial comparing melphalan-prednisone to melphalan-prednisone + alpha-interferon. The Nordic Myeloma Study Group.
Wisløff F; Hjorth M; Kaasa S; Westin J
Br J Haematol; 1996 Aug; 94(2):324-32. PubMed ID: 8759893
[TBL] [Abstract][Full Text] [Related]
27. Interferon versus interferon plus prednisone remission maintenance therapy for multiple myeloma: a Southwest Oncology Group Study.
Salmon SE; Crowley JJ; Balcerzak SP; Roach RW; Taylor SA; Rivkin SE; Samlowski W
J Clin Oncol; 1998 Mar; 16(3):890-6. PubMed ID: 9508170
[TBL] [Abstract][Full Text] [Related]
28. Treatment of multiple myeloma.
San Miguel JF; Bladé Creixenti J; García-Sanz R
Haematologica; 1999 Jan; 84(1):36-58. PubMed ID: 10091392
[TBL] [Abstract][Full Text] [Related]
29. Initial treatment in multiple myeloma: no advantage of multidrug chemotherapy over melphalan-prednisone. The Myeloma Group of Western Sweden.
Hjorth M; Hellquist L; Holmberg E; Magnusson B; Rödjer S; Westin J
Br J Haematol; 1990 Feb; 74(2):185-91. PubMed ID: 2180471
[TBL] [Abstract][Full Text] [Related]
30. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial.
Facon T; Mary JY; Hulin C; Benboubker L; Attal M; Pegourie B; Renaud M; Harousseau JL; Guillerm G; Chaleteix C; Dib M; Voillat L; Maisonneuve H; Troncy J; Dorvaux V; Monconduit M; Martin C; Casassus P; Jaubert J; Jardel H; Doyen C; Kolb B; Anglaret B; Grosbois B; Yakoub-Agha I; Mathiot C; Avet-Loiseau H;
Lancet; 2007 Oct; 370(9594):1209-18. PubMed ID: 17920916
[TBL] [Abstract][Full Text] [Related]
31. Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical study.
Cavo M; Benni M; Ronconi S; Fiacchini M; Gozzetti A; Zamagni E; Cellini C; Tosi P; Baccarani M; Tura S;
Haematologica; 2002 Sep; 87(9):934-42. PubMed ID: 12217805
[TBL] [Abstract][Full Text] [Related]
32. Interferon therapy during the plateau phase of multiple myeloma: an update of a Swedish multicenter study.
Westin J
Semin Oncol; 1991 Oct; 18(5 Suppl 7):37-40. PubMed ID: 1948128
[TBL] [Abstract][Full Text] [Related]
33. Alternating combination VCMP/VBAP chemotherapy versus melphalan/prednisone in the treatment of multiple myeloma: a randomized multicentric study of 487 patients.
Bladé J; San Miguel JF; Alcalá A; Maldonado J; Sanz MA; García-Conde J; Moro MJ; Alonso C; Besalduch J; Zubizarreta A
J Clin Oncol; 1993 Jun; 11(6):1165-71. PubMed ID: 8501503
[TBL] [Abstract][Full Text] [Related]
34. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial.
Mateos MV; Oriol A; Martínez-López J; Gutiérrez N; Teruel AI; de Paz R; García-Laraña J; Bengoechea E; Martín A; Mediavilla JD; Palomera L; de Arriba F; González Y; Hernández JM; Sureda A; Bello JL; Bargay J; Peñalver FJ; Ribera JM; Martín-Mateos ML; García-Sanz R; Cibeira MT; Ramos ML; Vidriales MB; Paiva B; Montalbán MA; Lahuerta JJ; Bladé J; Miguel JF
Lancet Oncol; 2010 Oct; 11(10):934-41. PubMed ID: 20739218
[TBL] [Abstract][Full Text] [Related]
35. A randomized clinical trial comparing melphalan/prednisone with or without interferon alfa-2b in newly diagnosed patients with multiple myeloma: a Cancer and Leukemia Group B study.
Cooper MR; Dear K; McIntyre OR; Ozer H; Ellerton J; Canellos G; Bernhardt B; Duggan D; Faragher D; Schiffer C
J Clin Oncol; 1993 Jan; 11(1):155-60. PubMed ID: 8418228
[TBL] [Abstract][Full Text] [Related]
36. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486.
Oken MM; Leong T; Lenhard RE; Greipp PR; Kay NE; Van Ness B; Keimowitz RM; Kyle RA
Cancer; 1999 Sep; 86(6):957-68. PubMed ID: 10491521
[TBL] [Abstract][Full Text] [Related]
37. Melphalan and prednisone (MP) versus vincristine, BCNU, adriamycin, melphalan and dexamethasone (VBAMDex) therapy for multiple myeloma. Early results of a multicenter trial. The German Myeloma Treatment Group.
Peest D; Deicher H; Coldewey R; von Broen IM; Cammerer U; Hein R; Hoffmann L; Konyar H; Kreuser ED; Selbach J
Onkologie; 1990 Feb; 13(1):43-4. PubMed ID: 2186324
[TBL] [Abstract][Full Text] [Related]
38. Continuous lenalidomide treatment for newly diagnosed multiple myeloma.
Palumbo A; Hajek R; Delforge M; Kropff M; Petrucci MT; Catalano J; Gisslinger H; Wiktor-Jędrzejczak W; Zodelava M; Weisel K; Cascavilla N; Iosava G; Cavo M; Kloczko J; Bladé J; Beksac M; Spicka I; Plesner T; Radke J; Langer C; Ben Yehuda D; Corso A; Herbein L; Yu Z; Mei J; Jacques C; Dimopoulos MA;
N Engl J Med; 2012 May; 366(19):1759-69. PubMed ID: 22571200
[TBL] [Abstract][Full Text] [Related]
39. A randomized trial of melphalan and prednisone versus melphalan, prednisone, cyclophosphamide, MeCCNU, and vincristine in untreated multiple myeloma.
Pavlovsky S; Saslavsky J; Tezanos Pinto M; Palmer L; Curuchet M; Lein JM; Garay G; Dragosky M; Quiroga-Micheo E; Huberman AB
J Clin Oncol; 1984 Jul; 2(7):836-40. PubMed ID: 6376722
[TBL] [Abstract][Full Text] [Related]
40. [Progress in the treatment of multiple myeloma].
Wada M; Mizoguchi H
Gan To Kagaku Ryoho; 1997 Jul; 24(9):1079-88. PubMed ID: 9239160
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]